Lilly partners with Nvidia on AI supercomputer to speed up drug development

Eli Lilly has teamed up with Nvidia to use artificial intelligence supercomputers to accelerate the development of new drugs. The partnership aims to improve the speed and efficiency of research, especially in cancer and immune-related diseases. By integrating Nvidia’s advanced computing capabilities, Lilly hopes to reduce the time and cost of bringing new treatments to market. This move highlights the growing role of AI in transforming pharmaceutical innovation.